Expression and Characterization of GSK-3 Mutants and Their Effect on Beta-catenin Phosphorylation in Intact Cells
Overview
Affiliations
Glycogen synthase kinase-3 (GSK-3) is a serine-threonine kinase that is involved in multiple cellular signaling pathways, including the Wnt signaling cascade where it phosphorylates beta-catenin, thus targeting it for proteasome-mediated degradation. Unlike phosphorylation of glycogen synthase, phosphorylation of beta-catenin by GSK-3 does not require priming in vitro, i.e. it is not dependent on the presence of a phosphoserine, four residues C-terminal to the GSK-3 phosphorylation site. Recently, a means of dissecting GSK-3 activity toward primed and non-primed substrates has been made possible by identification of the R96A mutant of GSK-3beta. This mutant is unable to phosphorylate primed but can still phosphorylate unprimed substrates (Frame, S., Cohen, P., and Biondi R. M. (2001) Mol. Cell 7, 1321-1327). Here we have investigated whether phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin requires priming through prior phosphorylation at Ser(45) in intact cells. We have shown that the Arg(96) mutant does not induce beta-catenin degradation but instead stabilizes beta-catenin, indicating that it is unable to phosphorylate beta-catenin in intact cells. Furthermore, if Ser(45) in beta-catenin is mutated to Ala, beta-catenin is markedly stabilized, and phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin by wild type GSK-3beta is prevented in intact cells. In addition, we have shown that the L128A mutant, which is deficient in phosphorylating Axin in vitro, is still able to phosphorylate beta-catenin in intact cells although it has reduced activity. Mutation of Tyr(216) to Phe markedly reduces the ability of GSK-3beta to phosphorylate and down-regulate beta-catenin. In conclusion, we have found that the Arg(96) mutant has a dominant-negative effect on GSK-3beta-dependent phosphorylation of beta-catenin and that targeting of beta-catenin for degradation requires prior priming through phosphorylation of Ser(45).
Sun Q, Liu B, Lan Q, Su Z, Fu Q, Wang L Int J Oncol. 2023; 63(5).
PMID: 37681484 PMC: 10546378. DOI: 10.3892/ijo.2023.5569.
Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration.
Rippin I, Eldar-Finkelman H Cells. 2021; 10(2).
PMID: 33572709 PMC: 7911291. DOI: 10.3390/cells10020262.
GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer.
Silva-Garcia O, Cortes-Vieyra R, Mendoza-Ambrosio F, Ramirez-Galicia G, Baizabal-Aguirre V Biomolecules. 2020; 10(12).
PMID: 33339170 PMC: 7765659. DOI: 10.3390/biom10121683.
Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness.
Castagnoli L, Tagliabue E, Pupa S Int J Mol Sci. 2020; 21(23).
PMID: 33260642 PMC: 7730964. DOI: 10.3390/ijms21239069.
Casein Kinase 1α as a Regulator of Wnt-Driven Cancer.
Shen C, Nayak A, Melendez R, Wynn D, Jackson J, Lee E Int J Mol Sci. 2020; 21(16).
PMID: 32824859 PMC: 7460588. DOI: 10.3390/ijms21165940.